| Name | Piclamilast |
| Description | Piclamilast (RP 73401) is a PDE4 inhibitor. |
| In vitro | Piclamilast pre-treatment significantly inhibited the changes in 23 genes via mechanisms involving AP-1 activation and c-Jun phosphorylation at Ser63[1]. The IC50s for Piclamilast was 16 nM and 2 nM in pig aorta and eosinophil soluble, respectively. Piclamilast exhibited IC50 values >100 μM, 40 μM, >100 μM, 14 μM for PDE1, PDE2, PDE3 and PDE5. Respectively[4]. |
| In vivo | Initial in vivo studies conducted in severe combined immunodeficiency mice transplanted with NB4 leukemia cells indicate that the enhancing effect of piclamilast on ATRA-induced myeloid maturation translates into a therapeutic benefit[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 30 mg/mL (78.69 mM), Sonication is recommended. 10% DMSO+90% Corn Oil : 2 mg/mL (5.25 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | RPR-73401 | RPR73401 | RP-73401 | RP73401 | RAR | Piclamilast | Phosphodiesterase (PDE) | phosphodiesterase | PDE4 | PDE | Inhibitor | inhibit | cAMP | ATRA | AML |
| Inhibitors Related | Balipodect | Theophylline monohydrate | D(+)-Raffinose pentahydrate | Theobromine | Apremilast | Isoprenaline hydrochloride | Indomethacin | Icariin | Theophylline | Vardenafil hydrochloride | Sildenafil citrate | Doxofylline |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | ReFRAME Related Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Human Metabolite Library |